Cargando…
Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review
Autores principales: | Rossignol, Patrick, Ruilope, Luis M, Cupisti, Adamasco, Ketteler, Markus, Wheeler, David C, Pignot, Marc, Cornea, Georgiana, Schulmann, Thierry, Lund, Lars H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467623/ https://www.ncbi.nlm.nih.gov/pubmed/32905252 http://dx.doi.org/10.1093/ckj/sfz129 |
Ejemplares similares
-
In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
por: Sciatti, Edoardo, et al.
Publicado: (2023) -
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021) -
Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function
por: Cupisti, Adamasco, et al.
Publicado: (2018) -
Renin-angiotensin-aldosterone system and kidney interactions in heart
failure
por: Ferreira, João Pedro, et al.
Publicado: (2019) -
Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)